ELOX, US29014R2022

Eloxx reported first Alport dosing: Eloxx Pharmaceuticals stock sits 61.70 percent below target

Published on 10/14/2026 at 03:39 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Eloxx posted a USD 4.50 million net loss in the second quarter of 2026. Eloxx Pharmaceuticals stock had USD 43.6 million value on October 13, 2026.

Clinical timeline and reporting schedule

Eloxx reported first patient dosing in the Alport study on September 11, 2026.
The company held USD 61.96 million in cash on June 30, 2026.
Eloxx is scheduled to report third-quarter 2026 results on November 11, 2026.

ELOX, US29014R2022, Illustration mit AI erstellt.

Eloxx Pharmaceuticals stock had a USD 43.6 million market value on October 13, 2026, while the USD 40.50 analyst target cited by Eulerpool stood 61.70 percent above its referenced USD 15.51 share price. StockTitan reported on September 11, 2026, that the company had announced first patients dosed in the Phase 2b EXACT study of exaluren for nonsense mutation Alport syndrome.

Three events define the timeline

On June 8, 2026, Eloxx priced a USD 66.00 million public offering and announced its Nasdaq uplisting, according to StockTitan. The financing matters because the company entered its renal clinical program with a larger liquidity base and a newly expanded share structure.

StockTitan listed August 12, 2026, as the date of Eloxx's second-quarter financial results and business update. The September 11 dosing announcement then shifted the timetable from financing toward clinical execution.

What does the cash position mean?

In the second quarter of 2026, Eloxx reported USD 0.00 revenue and a USD 4.50 million net loss, including USD 2.84 million of research and development expense, according to HDIN Research. The same review records USD 61.96 million in cash and a USD 46.42 million working-capital surplus as of June 30, 2026.

That liquidity came with a heavier spending pace: operating cash outflow reached USD 10.24 million in the first half of 2026, compared with USD 0.55 million in the first half of 2025, according to HDIN Research. The comparison puts the clinical runway and future financing needs alongside the trial milestone.

Reporting dates set the next checkpoints

Barron's lists November 11, 2026, for third-quarter 2026 results and March 3, 2027, for fiscal-year 2026 results. Those dates frame the next financial updates after the September clinical announcement.

Eloxx Pharmaceuticals is a clinical-stage biotechnology company developing small-molecule candidates for rare and ultra-rare genetic diseases. Its lead program is now tied to the Phase 2b Alport study, while the latest reported figures show a cash-rich balance sheet alongside accelerating clinical spending.

Market value and company profile

Finance data put Eloxx Pharmaceuticals at a USD 43.6 million market capitalization on October 13, 2026, with a 52-week range of USD 8.20 to USD 23.40. The company is identified as Eloxx Pharmaceuticals, Inc., ticker ELOX, with biotechnology as its industry and NASDAQ as its primary exchange.

Market context: Market report S&P 500.